title: Esthesioneuroblastomas with intracranial extension. Proliferative potential and management.
abstract: A total of 15 patients with esthesioneuroblastomas were treated between 1978 and 1992 at the Neurosurgery Department, Nordstadt Hospital, Hannover. In 9 cases, the tumors invaded the anterior cranial fossa. One patient died before any surgical intervention. Eight tumors were operated by a combined paranasal and subfrontal approach. Gross total tumor removal was achieved in all cases. Apart from anosmia, the only postoperative complication was transient mental changes in one case. Immunohistochemical analyses with MIB 1 monoclonal antibodies, directed against recombinant parts of Ki-67 antigen, were performed to estimate the proliferative potential of the esthesioneuroblastomas. Most of the tumors showed high proliferating cell indexes, which ranged from 3 to 42% (mean, 16%). The proliferating cell index with MIB 1 showed a correlation with postoperative outcome, although this was not statistically significant. Esthesioneuroblastomas can be totally removed surgically. The proliferating cell index may reflect histologically the biological behavior of tumor. Long-term follow-up is mandatory, and immunohistochemical studies may be of help in predicting outcome.
authors.affiliation: Nordstadt Hospital, Hannover, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Tatagiba
authors.forename: M
authors.initials: M
authors.lastname: Samii
authors.forename: E
authors.initials: E
authors.lastname: Dankoweit-Timpe
authors.forename: P H
authors.initials: PH
authors.lastname: Aguiar
authors.forename: L
authors.initials: L
authors.lastname: Osterwald
authors.forename: R
authors.initials: R
authors.lastname: Babu
authors.forename: H
authors.initials: H
authors.lastname: Ostertag
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D018304:Esthesioneuroblastoma, Olfactory / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009669:Nose Neoplasms / Q000473:pathology* / Q000628:therapy; D011379:Prognosis